VALENCIA, Calif. and WEST VALLEY CITY, Utah, Dec. 13, 2022 (GLOBE NEWSWIRE) — Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced Chris Lowe as the company’s Chief Executive Officer. As Nusano progresses toward commercialization, Lowe brings more than 30 years of business and financial leadership, including executive level leadership roles at pharmaceutical and medical device companies.
“In the fight against cancer, the clinical development of therapeutics and their availability are being dangerously limited by radioisotope supply shortages. Nusano intends to change that dynamic,” said Lowe. “We believe our foundational technology will shift the paradigm for patients, payors and clinicians, and help usher in an exciting new era in radiopharmaceuticals and diagnostics.”
Lowe has extensive experience in health care operations and finance, including clinical trials, pricing and reimbursement, mergers and acquisitions, equity and debt financings, and initial public offerings. As CEO, Lowe will be responsible for the strategic direction and operations of the company, including the construction of its state-of-the-art production facility in West Valley City, Utah.
